KLAS-TELECOM
Klas Telecom announced today they will supply the TRX Connected Transportation Platform to global engineering house Ikusi for a project to upgrade the passenger information systems onboard Renfe train fleets. Under a Memorandum of Understanding, Klas Telecom’s TRX platform will provide an onboard Wi-Fi infrastructure that improves connectivity to and within the train so that passengers have a better user experience accessing the mobile information and services they need. Klas Telecom and Ikusi have enjoyed a longstanding relationship in which they have worked together to design and develop bespoke solutions to deliver the exacting requirements stipulated by Ikusi’s railway customers.
Ikusi selected Klas Telecom’s TRX R6 as the key component of the onboard passenger Wi-Fi system. The TRX R6 will deliver reliable, high-bandwidth and low-latency connectivity to the train. Another key component of the passenger Wi-Fi system is the software-defined wide area network (SDWAN) feature of the TRX operating system, KlasOS. The KlasOS SDWAN aggregates WAN links and manages multiple wireless bearers in order to provide the train both higher throughput and availability of the offboard WAN link. Klas Telecom’s advanced SDWAN technology leverages any available Internet connection, whether in-station Wi-Fi or 3G/4G LTE connections. The KlasOS SDWAN feature seamlessly routes traffic over uncongested links to ensure that passengers stay connected at all times whether checking e-mails, updating social media, remote working over VPN or making a video call.
“Our partnership with Klas Telecom has gone from strength to strength in recent years,” Ikusi Director of Railway Solutions José Morales said. “We can count on their competence to develop the most appropriate solution to meet the project requirements every time. This Memorandum of Understanding ensures that Ikusi continues to work closer than ever to Klas Telecom, ultimately resulting in greater passenger satisfaction for our customers.”
Brendan Fleming, Klas Telecom Director of Business Development for Transportation, added, “Working with a partner like Ikusi allows us to demonstrate what we do best: developing and supplying the latest cutting-edge technology as part of an onboard Wi-Fi solution, allowing the end customer to provide an optimum passenger experience.”
You can view Klas Telecom’s TRX platform this week at InnoTrans 2018 in Hall 7.1B at Messe Berlin.
More About Klas Telecom
With a background in satellite communications, Klas Telecom is an engineering and design company with over 25 years of experience developing innovative communications solutions for the network edge. Klas Telecom delivers connectivity to communications black spots and austere environments where low size, weight, power and ruggedization are required. The company specializes in integrating enterprise networking capabilities from global IT leaders with in-house hardware and software platforms designed and proven against the most stringent environmental requirements. With over 80% of the company dedicated to technology development, Klas Telecom is able to stay on the forefront of the deployable communications technology. Klas Telecom operates in the public safety, transportation and U.S. and international defense markets. The company employs staff across four offices located in Washington, DC; Herndon, VA; Tampa, FL; and Dublin, Ireland. www.klastelecom.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180917005821/en/
Contact:
Klas Telecom Carrie Sarver Hall | VP of Marketing and Communications 202-288-6342 carrie.hall@klastelecom.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release
At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,
Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release
Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP
Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release
Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through
Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse
Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom